Latest news

• Regeneron’s Dupixent and Praluent fall short

  And another new launch - Kevzara (sarilumab) for rheumatoid arthritis - also missed expectations and made just $12m.

• After some big setbacks, Sanofi talks up its R&D portfolio

  antibody Praluent (alirocumab) for cholesterol-lowering, IL4 inhibitor Dupixent (dupilumab) for eczema and IL-6 blocker arthritis treatment Kevzara (sarilumab) as well as a clutch of late-stage pipeline projects - before

• Dupixent dulls pain of diabetes slump at Sanofi

  New rheumatoid arthritis therapy Kevzara (sarilumab), an IL-6 inhibitor predicted to become a $1bn-plus product despite entering a fairly crowded market, was approved in the US in May and

• NICE backs Sanofi's Kevzara for routine NHS use

  NICE backs Sanofi's Kevzara for routine NHS use. Recommends the RA treatment in combination with methotrexate. ... Sanofi is celebrating a positive recommendation from the UK’s cost effectiveness watchdog for its rheumatoid arthritis (RA) treatment

• FDA wants more data on J&J’s arthritis drug Plivensia

  An IL-6 inhibitor, Plivensia would compete with other drugs in the class, namely Roche’s well-established Actemra (tocilizumab) and Sanofi/Regeneron’s new entrant Kevzara (sarilumab), which claimed its ... Actemra made sales of $1.7bn last year, but